Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.